Low-Dose Aspirin Cuts Cancer Death Rate

| March 04, 2011
Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.

A recent study in the journal The Lancet suggests long-term, low-dose aspirin use reduces the risk of cancer-related death. The researchers analyzed cancer-related deaths in 8 clinical studies of aspirin involving >25,000 patients. At 20 years’ follow-up, patients in the aspirin arms were 20% less likely to die of cancer than patients in the placebo groups. Aspirin dosages were usually low—between 75 mg to 100 mg. The fi ndings will no doubt stoke the fl ames of the ongoing debate over whether healthy individuals should start taking aspirin. Despite the potential benefi ts, aspirin also increases the risk of bleeding in the stomach and brain.



Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Related Articles
By: Insights From: Samuel J. Klempner, MD, The Angeles Clinic and Research Institute; Cedar Sinai Medical Center; Alice Beers, RN, BSN, OCN, MedStar Health System
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Blogs
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2017
Intellisphere, LLC. All Rights Reserved.